

Aleksandar Sekulic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3028872/publications.pdf>

Version: 2024-02-01

24
papers

2,863
citations

623734

14
h-index

752698

20
g-index

24
all docs

24
docs citations

24
times ranked

3986
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2012, 366, 2171-2179.	27.0	1,201
2	Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. <i>Nature Genetics</i> , 2014, 46, 427-429.	21.4	298
3	Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. <i>BMC Cancer</i> , 2017, 17, 332.	2.6	291
4	Cutaneous adverse effects of targeted therapies. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 203-218.	1.2	191
5	Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 1021-1026.e8.	1.2	176
6	Cutaneous adverse effects of targeted therapies. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 221-236.	1.2	150
7	Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape. <i>Mayo Clinic Proceedings</i> , 2008, 83, 825-846.	3.0	120
8	Targeting TMPRSS2 in SARS-CoV-2 Infection. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1989-1999.	3.0	100
9	A Pharmacological Chaperone Molecule Induces Cancer Cell Death by Restoring Tertiary DNA Structures in Mutant hTERT Promoters. <i>Journal of the American Chemical Society</i> , 2016, 138, 13673-13692.	13.7	91
10	Hedgehog Pathway Inhibition. <i>Cell</i> , 2016, 164, 831.	28.9	62
11	Advanced basal cell carcinoma of the skin. <i>Current Opinion in Oncology</i> , 2013, 25, 218-223.	2.4	49
12	Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). <i>Rare Diseases (Austin, Tex)</i> , 2014, 2, e967148.	1.8	40
13	Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. <i>Cancer</i> , 2019, 125, 18-44.	4.1	29
14	The prognostic value of inositol polyphosphate 5-phosphatase in cutaneous squamous cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 626-632.e1.	1.2	16
15	Prognostic value of inositol polyphosphate-5-phosphatase expression in recurrent and metastatic cutaneous squamous cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 846-853.	1.2	14
16	Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, e205-e206.	1.2	13
17	Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry. <i>PLoS ONE</i> , 2022, 17, e0262151.	2.5	7
18	Treatment of epidermolysis bullosa pruriginosa using systemic and topical agents. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, e136-e137.	1.2	6

#	ARTICLE	IF	CITATIONS
19	Treatment of vismodegib-associated muscle cramps with cyclobenzaprine: A retrospective review. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 1170-1172.	1.2	6
20	Necrobiosis lipoidica-associated cutaneous malignancy. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1428-1429.	1.2	3
21	Title is missing!., 2020, 15, e0230306.		0
22	Title is missing!., 2020, 15, e0230306.		0
23	Title is missing!., 2020, 15, e0230306.		0
24	Title is missing!., 2020, 15, e0230306.		0